KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShort-Term Debt issuances
Ratios

Astrazeneca (AZN) Accumulated Depreciation & Amortization (2017 - 2023)

Astrazeneca has reported Accumulated Depreciation & Amortization over the past 6 years, most recently at $17.2 billion for Q4 2023.

  • For Q4 2023, Accumulated Depreciation & Amortization changed N/A year-over-year to $17.2 billion; the TTM value through Dec 2023 reached $17.2 billion, changed N/A, while the annual FY2023 figure was $17.2 billion, N/A changed from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2023 was $17.2 billion at Astrazeneca, up from $1.3 billion in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $17.2 billion in Q4 2023 and troughed at -$1.6 billion in Q4 2019.
  • A 4-year average of $4.2 billion and a median of $1.3 billion in 2021 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: plummeted 115.09% in 2019 and later surged 190.84% in 2021.
  • Year by year, Accumulated Depreciation & Amortization stood at -$1.6 billion in 2019, then grew by 9.64% to -$1.4 billion in 2020, then surged by 190.84% to $1.3 billion in 2021, then skyrocketed by 1245.16% to $17.2 billion in 2023.
  • Business Quant data shows Accumulated Depreciation & Amortization for AZN at $17.2 billion in Q4 2023, $1.3 billion in Q4 2021, and $5.2 billion in Q1 2021.